Who we are

Plowshare Therapies develops durable treatments for severe pediatric rare diseases with urgent unmet medical need. Our initial focus is Maple Syrup Urine Disease, advancing a gene therapy to restore normal metabolism early in life.

The company holds FDA Orphan Drug and Rare Pediatric Disease designations, signaling regulatory alignment and progress toward IND readiness. Our program builds on decades of translational research and clinical experience, pairing modern vector engineering with conservative development choices.

Plowshare is mission-locked at formation, ensuring stewardship, accountability, and long-term alignment with patient outcomes. The company emerged from decades of care within Amish and Mennonite communities, providing deep disease insight and a strong foundation for execution.